News

Systemic mastocytosis is rare in children, and this case was particularly rare because of its lone symptom.

A case report describes a woman diagnosed with and treated for systemic mastocytosis despite vague symptoms such as atypical skin lesions.

A recent article proposed unifying the 2001 WHO SM diagnostic criteria and revised criteria of the 2021 International Consensus Classification Group.

A new review recommended the use of sensitive mutation detection methods to better diagnose systemic mastocytosis (SM).

A new study suggests that the phenotype of advanced systemic mastocytosis patients might provide clinicians with tools to offer diagnoses and prognoses.

A recent report shows two specific prognostic scoring systems have the most accurate predictive value for advanced SM outcomes.

Data from part 1 of a phase 2 trial showed bezuclastinib resulted in an overall improvement of quality of life for non-advanced SM patients.

A recent study showed cellular markers CD25, CD30 and CD25 could help predict prognosis in patients with systemic mastocytosis.

In a recently published case study, a patient was diagnosed with SM via the Spanish Network on Mastocytosis (REMA) score.

Findings from the phase 2 PATHFINDER study presented at SOHO 2024 showed avapritinib had an overall positive effect in SM patients.